

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2008

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-50298
(Commission File Number)

98-0376008
(IRS Employer
Identification No.)

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, Israel 91390
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: 972-2-566-0001

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 7.01 REGULATION FD DISCLOSURE.

Oramed Pharmaceuticals, Inc. ("Oramed") has prepared a slide show that will be used in connection with presentations to be made from time to time to investors. A copy of the slide show is being furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. Pursuant to the rules of the Securities and Exchange Commission, the information contained in this report (including the exhibits) shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any filing by Oramed under such Act or the Securities Act of 1933, as amended.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 Slide Show Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 23, 2008

ORAMED PHARMACEUTICALS INC.

By: /s/ Nadav Kidron
Nadav Kidron
President, CEO and Director

Breakthrough
Technology
for a
Brighter Future

www.oramed.com



Safe Harbor

- Certain of the statements contained in this material are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the Company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements.

Oramed Pharmaceuticals


- OTC Bulletin Board: ORMP
- Company with oral drug delivery platform
- World leading scientific team
- Experienced management team
- Diverse product pipeline
- Oral Insulin (ORMD 0801): Flag Ship Product

Oramed's Delivery Platform



- Normal digestion involves degradation of proteins/peptides
- Breakdown by acidic pH of stomach + digestive enzymes
- Oramed's delivery technology ensures that
 - the orally delivered peptides reach the absorption site intact and biologically active
 - it enhances their absorption through the gut wall into the bloodstream

Diabetes



23.6 Million people suffer from Diabetes in the US alone (ADA, 2007)

246 Million Diabetics Worldwide (IDF, 2008)



Diabetes

■ Type 1 (Juvenile)

- Complete lack of insulin
- Insulin dependent, multiple injections required

■ Type 2 (Adult Onset)

- Progressive insulin resistance associated with diabetes.
- Require oral medications and over time may require injections.




Diabetes – Type II

- Progressive disease
- Initial treatment:
 - life-style modification
 - diet + exercise
- Oral medications
 - Reduce resistance
 - Stimulate insulin secretion
- Last stage: insulin

Stages of Type 2 Diabetes:

Criteria for advancing to next stage?
A1C not at target: $\leq 7.0\%$




Sources: American Diabetes Association and World Health Organization

The need for Oral Insulin

- Oral insulin is the only delivery system that **mimics the biological and physiological processes**
- With an **oral delivery system**, insulin can become an earlier treatment modality with higher compliance


Stages of Type 2 Diabetes:

Criteria for advancing to next stage?
A1C not at target: $\leq 7.0\%$





Sources: American Diabetes Association and World Health Organization

History of Development



Oral Insulin - Clinical Data

- Increase in Insulin Levels
- Decline in Glucose Levels
- Decline in C-Peptide Levels



Oramed's Product Pipeline

- **Oral Insulin**
 - Phase 2a trials completed July 2008
- **Rectal Insulin application**
 - Successful pre-clinical trials
 - Starting phase 1 in South Africa
- **Oral Flu Vaccine**
 - At pre-clinical phases



Competitive Landscape

Oral Insulin Capsule:

- Diabetology (UK, Phase 2)
- Emisphere Technologies (US, Phase 2)
- Biocon (India)
- Apollo Life Sciences (Australia, Phase 1)

Alternative Oral Insulin:

- Generex (Canada, Phase 3) – Buccal delivery
- Bional (US, Phase 3) – Sublingual delivery
- MannKind (US) -Inhaled delivery

Financial Summary



- Market cap: \$33 - \$44 million
- Cash on hand \$5.1 million (as of July 15, 2008)
- Company expects to burn approx \$1.2m per quarter, mostly R&D
- 56 Million Shares Outstanding
- Float 37 million
 - Major Shareholders
 - Nadav Kidron 18.4%
 - Zeev Bronfeld 10.9%
 - Hadassit 7.4%
 - Leonard Sank 5.8%

Management

■ Nadav Kidron, CEO

- Experience in a number of industries ranging from corporate law to technology startups. Founder of several technology start-ups.

■ Chaime Orlev, CFO

- Many years of experience in financial management in publically traded companies. Specializes in the hi-tech sector and is a certified public accountant

■ Leonard Sank, Director

- Entrepreneur and business man, currently the acting director of companies in many diversified fields.

■ Miriam Kidron PhD, CSO

- Top researcher at the Diabetes Unit of Hadassah Medical Center in Jerusalem for over 25 years. Leading researcher in the development of oral insulin.

■ Ehud Arbit MD, Director of R&D

- Served as the VP of medical research at Emisphere Technologies, Professor at Cornell University Medical College and was Division Head at Memorial Sloan Kettering Cancer Center.

■ Harold Jacob MD, Director

- Strong background in medical sciences as well as biotechnology and medical devices. Dr Jacob was the former medical director of Given Imaging.

Scientific Advisory Board

■ Derek LeRoith, MD

- Professor of Medicine and Chief of Endocrinology, Diabetes and Bone Disease unit, Mount Sinai NY.

■ Prof. Avram Herskho, MD, PhD

- Distinguished Professor in the Biochemistry unit in the B. Rappaport Faculty of Medicine in the Technion in Haifa. Noble Prize Laureate in Chemistry (2004) for the discovery of Ubiquitin- mediated protein degradation.

■ Ele Ferrannini, MD

- Prof. of Internal Medicine, University of Pisa school of Medicine. Professor of Medicine, Diabetes Unit Texas Health science center.

■ Nir Brazilai, MD

- Director for the institute of aging research. Member of Diabetes Research Center, Albert Einstein University college of Medicine.



Summary - Oramed

- Patented technology platform for oral delivery of medications
- In the pipeline:
 - Oral and rectal delivery of Insulin
 - Oral delivery of the flu-vaccine
- Strong management team, leading scientific team and clear proof of concept



Oramed in the News

- Oramed's Oral Insulin Capsule listed as one of the five most promising drugs entering Phase 1 Trials by Thompson Pharma
- Chosen from hundreds of companies to represent Israel at the President's Conference celebrating Israel's 60th birthday
- ADA Poster Presentation San Francisco, June 2008
- Accepted for EASD Poster Presentation Rome, September 2008

Breakthrough Technology for a Brighter Future



Nadav Kidron, CEO

nadav@oramed.com



